Current oncology最新文献

{"title":"Secondary Intracranial Hypertension During ATRA/ATO Therapy in High-Risk Acute Promyelocytic Leukemia: A Case Report and Practical Management Framework.","authors":"Luca Roeh, Nigel Schaeper, Sebastian Schröder, Jan Friedrich Scheitz, Dorothea Cornelia Voigt, Simon Schallenberg, Martin Janz, Philipp le Coutre, Sebastian Stintzing, Daniel Noerenberg","doi":"10.3390/curroncol33100611","DOIUrl":"https://doi.org/10.3390/curroncol33100611","url":null,"abstract":"<p><p>All-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) is the standard of care for acute promyelocytic leukemia (APL), including high-risk disease. Secondary intracranial hypertension (SIH), historically termed pseudotumor cerebri (PTC), is a recognized but uncommon and potentially therapy-limiting complication of retinoid exposure, reported predominantly in pediatric and young-adult patients and most frequently during induction. We report a 31-year-old man with high-risk microgranular APL in whom SIH was diagnosed during the first ATRA/ATO consolidation cycle. The clinical course included progressive headache, ocular pain, pulsatile tinnitus, focusing difficulties, visual deterioration, and diplopia. Ophthalmological assessment demonstrated bilateral papilledema with marked peripapillary retinal nerve fiber layer thickening despite preserved central visual acuity. Magnetic resonance imaging showed bilateral optic nerve sheath distension, prominent optic nerve heads, mild pituitary flattening, and bilateral transverse sinus stenosis. Lumbar puncture demonstrated an opening pressure of 32 cm H₂O with otherwise unremarkable cerebrospinal fluid; removal of approximately 30 mL resulted in immediate symptomatic improvement. Management consisted of temporary ATRA interruption, therapeutic lumbar punctures, acetazolamide, and individualized ATRA rechallenge and dose titration. Repeated attempts at dose escalation reproduced symptoms, and ATRA was ultimately maintained at a maximally tolerated dose of 30 mg/m²/day while full-dose ATO was continued. Molecular remission was achieved after the first consolidation cycle and remains sustained at 18-month follow-up. This case highlights the importance of recognizing ATRA-associated SIH throughout the treatment course and illustrates a pragmatic strategy for preserving ATRA exposure when standard-dose treatment is limited by neurological toxicity. However, the oncological equivalence of reduced-dose ATRA cannot be inferred from a single case.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Prognostic Value of the Preoperative Prognostic Nutritional Index and Gustave Roussy Immune Score After Curative-Intent Gastrectomy for Gastric Cancer.","authors":"Ahmet Sencer Ergin, Mustafa Can Alıklı, Ali Karabulut, Alparslan Saylar, Nihat Buğdaycı, Turan Pehlivan, Serhat Meriç, Ali Naki Yücesoy, Erkan Yavuz, Osman Bilgin Gülçiçek","doi":"10.3390/curroncol33100610","DOIUrl":"https://doi.org/10.3390/curroncol33100610","url":null,"abstract":"<p><strong>Background/objectives: </strong>We compared the prognostic performance of preoperative prognostic nutritional index (PNI) and Gustave Roussy Immune Score (GRIm-s) after curative-intent gastrectomy.</p><p><strong>Methods: </strong>This retrospective cohort included 168 patients, including five postoperative in-hospital deaths. Continuous PNI and ordinal GRIm-s were compared using censoring-adjusted time-dependent AUC and concordance, with paired bootstrap confidence intervals. Preoperative prediction models underwent bootstrap internal validation; restricted mean survival time and time-varying Cox analyses addressed non-proportional hazards.</p><p><strong>Results: </strong>There were 92 deaths and 107 disease-free survival (DFS) events. At 36 months, overall survival (OS) AUC was 0.659 for PNI and 0.527 for GRIm-s (difference 0.132, 95% CI 0.039-0.226); corresponding DFS values were 0.650 and 0.516 (difference 0.134, 95% CI 0.035-0.228). After optimism correction, preoperative PNI-model AUCs were 0.610 for OS and 0.595 for DFS. PNI associations weakened over time. The cohort-derived 49.6 threshold was used only in secondary exploratory analyses.</p><p><strong>Conclusions: </strong>PNI showed better unadjusted discrimination than GRIm-s at three years, but modest internally validated model performance limits clinical interpretation. These findings do not establish clinical utility, a validated cutoff, or a substitute for pathological assessment. External validation is required.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Patient Perspectives and Acceptability of Integrative Naturopathic Oncology in Metastatic Cancer.","authors":"Sara Izadi-Najafabadi, Adeleke Fowokan, Gurdev Parmar","doi":"10.3390/curroncol33100609","DOIUrl":"https://doi.org/10.3390/curroncol33100609","url":null,"abstract":"<p><p>Individuals living with metastatic cancer frequently experience high symptom burden and reduced quality of life, leading many to seek integrative therapies alongside standard care. This study utilized the Theoretical Framework of Acceptability to systematically examine patient perspectives and the acceptability of integrative naturopathic oncology. Qualitative, semi-structured virtual interviews were conducted with 12 adult metastatic cancer patients who had received at least three months of care at a specialized Canadian clinic. The hybrid inductive-deductive analysis revealed high overall intervention acceptability. Patients reported positive emotional attitudes, strong alignment with personal values, improved treatment understanding, and increased confidence in managing their care. They particularly valued relational support, whole-person care, and an enhanced sense of agency. However, key implementation barriers included significant out-of-pocket expenses, social and family trade-offs, and navigating disconnected, uncoordinated healthcare systems. Integrative naturopathic oncology is highly acceptable to metastatic cancer patients as a valued complement to conventional regimens. To optimize equitable and safe care delivery, future health systems must reduce financial barriers and introduce structured communication channels between conventional and integrative health providers.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olink Platform-Based Identification of Peripheral Blood Biomarkers for irAEs in Advanced NSCLC.","authors":"Zhihan Zhang, Bingchun Chen, Hanmei Jiang, Ziyan Zhang, Jianming Mo, Yanyi Hou, Shuang Liu, Ping Xu","doi":"10.3390/curroncol33100605","DOIUrl":"https://doi.org/10.3390/curroncol33100605","url":null,"abstract":"<p><p>Lung cancer is the leading cause of cancer-related mortality worldwide. Immunotherapy has transformed the treatment landscape for advanced non-small cell lung cancer (NSCLC). However, immune-related adverse events (irAEs) represent a major clinical challenge during immunotherapy. These events can affect any organ system, and severe irAEs may necessitate treatment interruption or lead to life-threatening outcomes. We prospectively enrolled 84 advanced NSCLC patients treated with immunotherapy (June 2022-June 2024, followed until February 2025), including 57 who developed grade 1-4 irAEs and 27 who did not. Peripheral blood was collected from 39 patients at baseline for Olink platform-based proteomic screening, complemented by flow cytometric analysis of lymphocyte subsets. Olink profiling revealed IL13 and TRAIL as the most significantly differentially expressed proteins between irAEs and non-irAE groups. These proteins were enriched in biological processes such as negative regulation of lung ciliated cell differentiation and positive regulation of lung goblet cell differentiation, as well as in asthma and inflammatory bowel disease pathways. Moreover, dynamic changes in total T lymphocytes, T helper cells, NK cells, and the CD4/CD8 ratio were strongly associated with irAE occurrence. These markers, readily measurable in peripheral blood, offer potential for early risk stratification and real-time monitoring.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretable Machine Learning Prognostic Model Integrating Inflammatory-Nutritional Biomarkers for Post-Prostatectomy Biochemical Recurrence: Development, Internal Validation, and Translational Target Exploration.","authors":"Hao Wang, Yifei Zhang, Zhen Li, Jiyue Wu, Huawei Cao, Lijian Gan, Xuemeng Qiu, Wei Wang","doi":"10.3390/curroncol33100608","DOIUrl":"https://doi.org/10.3390/curroncol33100608","url":null,"abstract":"<p><p><b>Objective</b>: Biochemical recurrence (BCR) after laparoscopic radical prostatectomy (LRP) significantly affects the long-term survival of prostate cancer (PCa) patients. This study aimed to develop and validate an interpretable machine learning model integrating clinicopathological characteristics and preoperative inflammatory and nutritional indices to predict recurrence-free survival (RFS) and explore potential molecular therapeutic targets. <b>Methods</b>: A retrospective cohort of 320 PCa patients undergoing LRP at Beijing Chaoyang Hospital, Capital Medical University was analyzed. We integrated demographic, clinicopathological variables, and seven composite inflammatory/nutritional indices before LRP. A Mime-based machine learning survival pipeline was employed, combining Cox-based feature selection with survival algorithms. Model performance was evaluated using the concordance index (C-index), time-dependent ROC, calibration curves, and decision curve analysis (DCA). SHAP (SHapley Additive exPlanations) was used for model interpretation and deriving clinical cutoffs. Furthermore, intersecting genes of BCR, lymphocyte-to-monocyte ratio (LMR), and prognostic nutritional index (PNI) were identified via GeneCards, followed by drug sensitivity screening and molecular docking. <b>Results</b>: The StepCox[both] combined with Random Survival Forest model demonstrated optimal performance, achieving a validation C-index of 0.788. SHAP analysis identified the top five predictive factors for recurrence: preoperative LMR, PNI score, postoperative Gleason score ≥ 8, positive surgical margin, and lymphovascular invasion. Model-derived cutoffs were determined as LMR = 3.9 and PNI = 48.8. Intersection analysis revealed 1211 shared targets among BCR, LMR, and PNI, with TP53 and PTEN ranking highest. Drug sensitivity analysis and molecular docking suggested potential inhibitory effects of compounds like sabutoclax and dordaviprone on these targets. <b>Conclusions</b>: The proposed model may serve as a robust and interpretable risk stratification for postoperative PCa patients. The integration of clinical phenotyping with exploratory molecular docking offers a translational pathway from prognostic indices to potential therapeutic hypotheses, warranting further prospective validation.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Immunotherapy and Immune-Related Adverse Events: Focusing on Non-Small Cell Lung Cancer.","authors":"Atif Kamil, Sara Cowles, Casaundra C Driver, Aakriti Arora, Madison M Swyers, Luke W Boldt, Mahvish Muzaffar, Sameer A Batoo, Li V Yang","doi":"10.3390/curroncol33100607","DOIUrl":"https://doi.org/10.3390/curroncol33100607","url":null,"abstract":"<p><p>The development of immunotherapy has changed the paradigm of cancer treatment. In particular, immune checkpoint inhibitors (ICIs) demonstrate therapeutic efficacy and improve patient survival across multiple cancer types. Currently, however, only a subset of cancer patients can achieve objective therapeutic responses and gain survival benefits from immunotherapy. Treatment-associated side effects, namely immune-related adverse events (irAEs), may cause autoimmune and inflammatory complications in various organ systems and hinder the use of immunotherapy in cancer patients. Herein, the development of cancer immunotherapy and the modulatory roles of the tumor immune microenvironment, with a focus on ICI therapy in non-small cell lung cancer (NSCLC), are reviewed. The grading, types, biomarkers, and treatment of irAEs are also discussed. More research is needed to further increase the efficacy of cancer immunotherapy and alleviate irAEs.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Tumor DNA (ctDNA) for Minimal Residual Disease (MRD) Detection in Colorectal Cancer (CRC): Current Evidence, Clinical Applications, and Future Directions.","authors":"Hannah Hyde, Emma Mageau, Chelsea M Leduc, Mitul J Madhu, Noah Dickinson, Tafheem-Un Nisa, Karolina M Czajka, Stacey A Santi, Prashant Jani, Grace W Ma, Sujeenthar Tharmalingam","doi":"10.3390/curroncol33100606","DOIUrl":"https://doi.org/10.3390/curroncol33100606","url":null,"abstract":"<p><p>Minimal residual disease (MRD) is a major contributor to colorectal cancer (CRC) recurrence following curative-intent treatment, yet conventional surveillance methods may fail to detect residual disease at its earliest stages. Circulating tumor DNA (ctDNA) has emerged as a minimally invasive biomarker for MRD detection and postoperative monitoring. We conducted a structured PubMed-based literature review and included 94 publications evaluating ctDNA in CRC. Across the literature, postoperative ctDNA positivity was consistently associated with increased recurrence risk and poorer disease-free and overall survival, while serial monitoring improved detection sensitivity and enabled assessment of treatment response. ctDNA frequently identified molecular recurrence approximately 2.5-11.5 months before conventional surveillance. Both tumor-informed and tumor-naive strategies were represented, using PCR/ddPCR, targeted next-generation sequencing, whole-exome or whole-genome sequencing, methylation-based assays, and emerging multiomic approaches. Although ctDNA demonstrates strong prognostic value, evidence supporting treatment modification based solely on ctDNA status remains limited. Further prospective randomized trials, assay standardization, and consensus clinical guidelines are required before routine implementation. Overall, ctDNA is a promising tool for recurrence prediction, surveillance, and precision management of CRC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Prognostic Significance of the H-Index and Systemic Inflammatory Parameters in IDH-Wildtype Glioblastoma Survival.","authors":"Havva Yeşil, Bekir Demirel, Ercan Gumusburun","doi":"10.3390/curroncol33100604","DOIUrl":"https://doi.org/10.3390/curroncol33100604","url":null,"abstract":"<p><p><b>Background:</b> IDH-wildtype Glioblastoma is characterized by an aggressive clinical course. This study aimed to evaluate the prognostic value of the H-index, the hemoglobin-albumin-lymphocyte-platelet (HALP) score and the aggregate index of systemic inflammation (AISI). <b>Methods:</b> We retrospectively analyzed 136 patients who underwent frontline chemoradiotherapy. <b>Results:</b> Optimal cut-offs were 20.94 for HALP, 2.29 for H-index, and 989.64 for AISI. A high H-index was associated with shorter overall survival (OS) in univariate analysis (<i>p</i> = 0.007) and showed the highest time-dependent AUC for OS among the three indices. In multivariable Cox models, comorbidities (<i>p</i> = 0.043), subtotal resection (<i>p</i> < 0.001), corticosteroid use (<i>p</i> = 0.040), and a low HALP score (<i>p</i> = 0.012) were associated with poor OS, whereas the associations for a high H-index (<i>p</i> = 0.084) and a high AISI (<i>p</i> = 0.036) did not meet the Bonferroni-adjusted significance threshold. In a sensitivity analysis restricted to patients not receiving corticosteroids (<i>n</i> = 80), H-index-based stratification remained associated with OS (median 14.4 vs. 24.9 months, log-rank <i>p</i> = 0.025), whereas the association for AISI was not retained. <b>Conclusions:</b> The H-index, evaluated here for the first time, and the HALP score may provide complementary prognostic information. Given the retrospective single-center design, the potential influence of corticosteroids, and the data-driven cut-offs, these findings should be regarded as exploratory and require external validation before clinical application.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort Study.","authors":"Zhenhong Ren, Jianchao Lu","doi":"10.3390/curroncol33100603","DOIUrl":"https://doi.org/10.3390/curroncol33100603","url":null,"abstract":"<p><strong>Background: </strong>Rheumatic immune-related adverse events (R-irAEs) after immune checkpoint inhibitor (ICI) therapy in lung cancer can be difficult to distinguish from cancer-related or degenerative musculoskeletal symptoms.</p><p><strong>Methods: </strong>In this single-center retrospective cohort, we analyzed 768 ICI-treated patients and a nested questionnaire cohort to characterize rheumatologist-confirmed R-irAEs, baseline associated factors, and patient-reported outcomes. Missing baseline C-reactive protein (CRP) was handled using multiple imputation.</p><p><strong>Results: </strong>New musculoskeletal symptoms occurred in 177 patients (23.0%), and 66 patients (8.6%) had confirmed R-irAEs. The leading phenotypes were inflammatory arthritis (<i>n</i> = 22), inflammatory arthralgia (<i>n</i> = 15), and polymyalgia rheumatica-like syndrome (<i>n</i> = 13). In multivariable analysis, female sex (adjusted odds ratio [OR] 2.21, 95% confidence interval [CI] 1.31-3.74), baseline CRP > 10 mg/L (OR 2.08, 95% CI 1.14-3.81), and pre-existing autoimmune disease (OR 5.24, 95% CI 2.37-11.57) were associated with confirmed R-irAEs. Among 437 questionnaire responders, confirmed R-irAEs were associated with worse pain, morning stiffness, disability, fatigue, and health status than non-confirmed musculoskeletal symptoms (all Holm-adjusted <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>Confirmed R-irAEs affected a measurable minority of ICI-treated patients with lung cancer and were associated with worse post-treatment patient-reported outcomes. Because baseline patient-reported outcomes were unavailable, these findings should not be interpreted as R-irAE-attributable change.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induction Systemic Therapy Followed by Response-Adapted Consolidative Radiation in Locally Advanced Non-Melanoma Skin Cancer: A Retrospective Case Series.","authors":"Poorva Vaidya, Tali Azenkot, John Bliamptis, Mitchell Toby Victor, Anna Dornisch, Jennifer Chang, Parag Sanghvi, Theresa Guo, Soo J Park","doi":"10.3390/curroncol33100602","DOIUrl":"https://doi.org/10.3390/curroncol33100602","url":null,"abstract":"<p><strong>Background: </strong>There exists an unmet clinical need to define definitive management strategies for patients with locally advanced non-melanoma skin cancers (NMSC), particularly if not amenable to surgical resection.</p><p><strong>Methods: </strong>We retrospectively reviewed a case series of locally advanced unresectable NMSC treated with induction systemic treatment followed by response-adapted consolidative radiation.</p><p><strong>Results: </strong>We identified 15 patients who met study criteria, including seven with basal cell carcinoma (BCC), six with cutaneous squamous cell carcinoma (CSCC), and two with Merkel cell carcinoma (MCC). Clinical complete response (CR) by physical examination was observed in all 15 patients. No locoregional or distant recurrences were observed in any histologic subtype after completion of radiation (median follow-up from completion of radiation: 18.1 months BCC, 22.5 months CSCC, 22.7 months MCC). The median duration of observed response (DOOR), measured from first clinical response was 26.9 months (26.2 BCC, 29.4 CSCC, 27.1 MCC). Radiation treatment volumes were response-adapted with median gross tumor volume reduction of 55.3% (15.3%-100%). Median treatment-free response was 20.5 months. No unexpected systemic therapy related toxicities were identified.</p><p><strong>Conclusions: </strong>In this single-institution retrospective case series, induction systemic therapy followed by response-adapted consolidative radiation was feasible and associated with durable disease control in selected patients with locally advanced unresectable NMSC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}